$KPTI
Karyopharm Therapeutics Inc. Stock $kpti

$kpti Overview Financials Valuation SEC Filings Company Website

2014 Q2 Form 10-Q Financial Statement

#000110465914036479 Filed on May 08, 2014

Income Statement

Concept	2014 Q2	2014 Q1	2013 Q1
Revenue	$21.00K	$171.0K	$233.0K
YoY Change	-84.21%	-26.61%	585.29%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$3.310M	$2.900M	$880.0K
YoY Change	252.13%	229.55%
% of Gross Profit
Research & Development	$13.16M	$10.98M	$4.965M
YoY Change	117.15%	121.13%
% of Gross Profit
Depreciation & Amortization	$50.00K	$40.00K	$30.00K
YoY Change	25.0%	33.33%
% of Gross Profit
Operating Expenses	$16.47M	$13.88M	$5.844M
YoY Change	135.17%	137.56%	45.48%
Operating Profit	-$16.45M	-$13.71M	-$5.611M
YoY Change	139.42%	144.38%	40.87%
Interest Expense	$20.00K	$20.00K	$0.00
YoY Change
% of Operating Profit
Other Income/Expense, Net	$17.00K	$18.00K
YoY Change	1600.0%
Pretax Income	-$16.43M	-$13.69M	-$5.610M
YoY Change	139.16%	144.03%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$16.43M	-$13.69M	-$5.610M
YoY Change	139.17%	144.1%
Net Earnings / Revenue	-78242.86%	-8008.19%	-2407.73%
Basic Earnings Per Share
Diluted Earnings Per Share	-$553.9K	-$462.3K	-$203.3K
COMMON SHARES
Basic Shares Outstanding	29.76M shares	29.75M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2014 Q2	2014 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$132.3M	$144.9M
YoY Change	647.46%
Cash & Equivalents	$132.3M	$144.9M
Short-Term Investments
Other Short-Term Assets	$3.000M	$2.700M
YoY Change	500.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$135.3M	$147.6M
YoY Change	643.31%
LONG-TERM ASSETS
Property, Plant & Equipment	$604.0K	$322.0K
YoY Change	101.33%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.392M	$997.0K
YoY Change
Total Long-Term Assets	$2.396M	$1.719M
YoY Change	698.67%
TOTAL ASSETS
Total Short-Term Assets	$135.3M	$147.6M
Total Long-Term Assets	$2.396M	$1.719M
Total Assets	$137.7M	$149.3M
YoY Change	644.21%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.456M	$3.273M
YoY Change	103.29%
Accrued Expenses	$2.003M	$1.550M
YoY Change	150.38%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$5.647M	$5.015M
YoY Change	125.88%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$151.0K	$170.0K
YoY Change
Total Long-Term Liabilities	$151.0K	$170.0K
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$5.647M	$5.015M
Total Long-Term Liabilities	$151.0K	$170.0K
Total Liabilities	$5.999M	$5.185M
YoY Change	139.96%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock	$3.000K	$3.000K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$131.7M	$144.1M
YoY Change
Total Liabilities & Shareholders Equity	$137.7M	$149.3M
YoY Change	644.21%

Cashflow Statement

Concept	2014 Q2	2014 Q1	2013 Q1
OPERATING ACTIVITIES
Net Income	-$16.43M	-$13.69M	-$5.610M
YoY Change	139.17%	144.1%
Depreciation, Depletion And Amortization	$50.00K	$40.00K	$30.00K
YoY Change	25.0%	33.33%
Cash From Operating Activities	-$11.88M	-$10.57M	-$5.160M
YoY Change	93.17%	104.84%
INVESTING ACTIVITIES
Capital Expenditures	-$320.0K	$125.0K	$0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$0.00	-$400.0K	$0.00
YoY Change
Cash From Investing Activities	-$320.0K	-$530.0K	$0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-380.0K	10.00K	5.530M
YoY Change	-101.65%	-99.82%
NET CHANGE
Cash From Operating Activities	-11.88M	-10.57M	-5.160M
Cash From Investing Activities	-320.0K	-530.0K	0.000
Cash From Financing Activities	-380.0K	10.00K	5.530M
Net Change In Cash	-12.58M	-11.09M	370.0K
YoY Change	-174.39%	-3097.3%
FREE CASH FLOW
Cash From Operating Activities	-$11.88M	-$10.57M	-$5.160M
Capital Expenditures	-$320.0K	$125.0K	$0.00
Free Cash Flow	-$11.56M	-$10.70M	-$5.160M
YoY Change	87.97%	107.27%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	us-gaap	Sales Revenue Net SalesRevenueNet	1437000	USD
CY2014Q1	us-gaap	Area Of Real Estate Property AreaOfRealEstateProperty	29933
CY2013Q4	us-gaap	Preferred Stock Value PreferredStockValue		USD
CY2014Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2013Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2014Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2013Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2014Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-13694000	USD
CY2014Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	29618879	shares
CY2013Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	29587258	shares
CY2013Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-5611000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-76263000	USD
CY2014Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	29618879	shares
CY2014Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.46
CY2013Q1	us-gaap	Sales Revenue Net SalesRevenueNet	233000	USD
CY2013Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	29587258	shares
CY2014Q1	us-gaap	Sales Revenue Net SalesRevenueNet	171000	USD
CY2013Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.52
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-24.70
CY2014Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10979000	USD
CY2013Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4965000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	63814000	USD
CY2014Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2904000	USD
CY2013Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	879000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	13721000	USD
CY2014Q1	us-gaap	Operating Expenses OperatingExpenses	13883000	USD
CY2013Q1	us-gaap	Operating Expenses OperatingExpenses	5844000	USD
	us-gaap	Operating Expenses OperatingExpenses	77535000	USD
CY2014Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-13712000	USD
CY2013Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-5611000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-76098000	USD
CY2014Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	29606683	shares
CY2013Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	2225596	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	3087622	shares
CY2014Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	43000	USD
CY2014Q1	us-gaap	Share Based Compensation ShareBasedCompensation	2846000	USD
CY2013Q1	us-gaap	Share Based Compensation ShareBasedCompensation	204000	USD
CY2013Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	34000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	393000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	7354000	USD
	kpti	Noncash Consulting Expense NoncashConsultingExpense	788000	USD
	us-gaap	Paid In Kind Interest PaidInKindInterest	188000	USD
CY2014Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	691000	USD
CY2013Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	120000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2673000	USD
CY2014Q1	dei	Entity Registrant Name EntityRegistrantName	Karyopharm Therapeutics Inc.
CY2014Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001503802
CY2014Q1	dei	Document Type DocumentType	10-Q
CY2014Q1	dei	Document Period End Date DocumentPeriodEndDate	2014-03-31
CY2014Q1	dei	Amendment Flag AmendmentFlag	false
CY2014Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2014Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2014Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2014Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2014
CY2014Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2014Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	29762499	shares
CY2014Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	144893000	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	155974000	USD
CY2014Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2673000	USD
CY2013Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1982000	USD
CY2014Q1	us-gaap	Assets Current AssetsCurrent	147566000	USD
CY2013Q4	us-gaap	Assets Current AssetsCurrent	157956000	USD
CY2014Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	997000	USD
CY2013Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	30000	USD
CY2014Q1	us-gaap	Assets Assets	149285000	USD
CY2013Q4	us-gaap	Assets Assets	158226000	USD
CY2014Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	3273000	USD
CY2013Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1740000	USD
CY2014Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	149285000	USD
CY2013Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	158226000	USD
CY2014Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1550000	USD
CY2013Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1168000	USD
CY2014Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	57000	USD
CY2013Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	79000	USD
CY2014Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	135000	USD
CY2013Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	116000	USD
CY2014Q1	us-gaap	Liabilities Current LiabilitiesCurrent	5015000	USD
CY2013Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3292000	USD
CY2014Q1	us-gaap	Common Stock Value CommonStockValue	3000	USD
CY2013Q4	us-gaap	Common Stock Value CommonStockValue	3000	USD
CY2014Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	220360000	USD
CY2013Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	217500000	USD
CY2014Q1	us-gaap	Development Stage Enterprise Deficit Accumulated During Development Stage DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage	76263000	USD
CY2013Q4	us-gaap	Development Stage Enterprise Deficit Accumulated During Development Stage DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage	62569000	USD
CY2014Q1	us-gaap	Stockholders Equity StockholdersEquity	144100000	USD
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	154934000	USD
CY2014Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-13694000	USD
CY2013Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-5611000	USD
CY2014Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1533000	USD
CY2013Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	376000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	3273000	USD
CY2014Q1	kpti	Increase Decrease In Accrued Liabilities And Other Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherLiabilities	383000	USD
CY2013Q1	kpti	Increase Decrease In Accrued Liabilities And Other Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherLiabilities	-7000	USD
	kpti	Increase Decrease In Accrued Liabilities And Other Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherLiabilities	1553000	USD
CY2014Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-22000	USD
CY2013Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-33000	USD
CY2013Q1	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	5530000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	212335000	USD
	kpti	Proceeds From Sale Of Convertible Preferred Stock Net Of Issuance Costs ProceedsFromSaleOfConvertiblePreferredStockNetOfIssuanceCosts	98754000	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	13000	USD
CY2013Q1	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	3000000	USD
CY2013Q1	kpti	Proceeds From Sale Of Convertible Preferred Stock Net Of Issuance Costs ProceedsFromSaleOfConvertiblePreferredStockNetOfIssuanceCosts	2500000	USD
	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	200000	USD
CY2013Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	30000	USD
CY2014Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	13000	USD
CY2014Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	715000	USD
CY2013Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	590000	USD
CY2014Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	393000	USD
CY2013Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	350000	USD
CY2014Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	322000	USD
CY2013Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	240000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	57000	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-10569000	USD
CY2014Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	170000	USD
CY2013Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-5157000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-66327000	USD
CY2014Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	125000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	715000	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-525000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-1115000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	113177000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	354000	USD
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	250000	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	-11081000	USD
CY2013Q1	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	373000	USD
	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	144893000	USD
	us-gaap	Stock Issued1 StockIssued1	13980000	USD
	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	99691000	USD
	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	750000	USD
	us-gaap	Notes Issued1 NotesIssued1	700000	USD
CY2014Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	415000	USD
CY2013Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	100000	USD
CY2014Q1	kpti	Accrued Research And Development Costs Current AccruedResearchAndDevelopmentCostsCurrent	314000	USD
CY2013Q4	kpti	Accrued Research And Development Costs Current AccruedResearchAndDevelopmentCostsCurrent	698000	USD
CY2014Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	469000	USD
CY2013Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	215000	USD
CY2014Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	352000	USD
CY2013Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	155000	USD
CY2014Q1	us-gaap	Lessee Leasing Arrangements Operating Leases Term Of Contract LesseeLeasingArrangementsOperatingLeasesTermOfContract	P161D
CY2014Q1	us-gaap	Operating Leases Rent Expense Minimum Rentals OperatingLeasesRentExpenseMinimumRentals	506000	USD
CY2014Q1	us-gaap	Operating Leases Rent Expense Contingent Rentals OperatingLeasesRentExpenseContingentRentals	898000	USD
CY2014Q1	kpti	Operating Leases Allowance For Improvements OperatingLeasesAllowanceForImprovements	1000000	USD
CY2014Q1	kpti	Annual Interest Rate AnnualInterestRate	0.08	pure
CY2014Q1	us-gaap	Security Deposit SecurityDeposit	400000	USD
CY2014Q1	kpti	Security Deposit Which May Be Reduced In Future SecurityDepositWhichMayBeReducedInFuture	200000	USD
CY2014Q1	kpti	Amount Of Operating Lease For Which Allowance For Improvements Is Provided AmountOfOperatingLeaseForWhichAllowanceForImprovementsIsProvided	449000	USD
CY2014Q1	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	400000	USD
CY2014Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	18000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-165000	USD
CY2014Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	967000	USD
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	997000	USD
CY2014Q1	us-gaap	Increase In Restricted Cash IncreaseInRestrictedCash	400000	USD
	us-gaap	Increase In Restricted Cash IncreaseInRestrictedCash	400000	USD
CY2013Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2014Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2014Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2013Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2013Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-76263000	USD
CY2014Q1	kpti	Operating Lease Scheduled Rent Payments Due OperatingLeaseScheduledRentPaymentsDue	5600000	USD
CY2014Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2013Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2014Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares

Files In Submission

Name	View Source	Status
0001104659-14-036479-index-headers.html	Edgar Link	pending
0001104659-14-036479-index.html	Edgar Link	pending
0001104659-14-036479.txt	Edgar Link	pending
0001104659-14-036479-xbrl.zip	Edgar Link	pending
a14-11693_110q.htm	Edgar Link	pending
a14-11693_1ex31d1.htm	Edgar Link	pending
a14-11693_1ex31d2.htm	Edgar Link	pending
a14-11693_1ex32d1.htm	Edgar Link	pending
a14-11693_1ex32d2.htm	Edgar Link	pending
a14-11693_1ex99d1.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
g116931mm01i001.gif	Edgar Link	pending
kpti-20140331.xml	Edgar Link	completed
kpti-20140331.xsd	Edgar Link	pending
kpti-20140331_cal.xml	Edgar Link	unprocessable
kpti-20140331_def.xml	Edgar Link	unprocessable
kpti-20140331_lab.xml	Edgar Link	unprocessable
kpti-20140331_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$KPTI
Karyopharm Therapeutics Inc. Stock $kpti

2014 Q2 Form 10-Q Financial Statement

#000110465914036479 Filed on May 08, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$KPTI Karyopharm Therapeutics Inc. Stock $kpti

2014 Q2 Form 10-Q Financial Statement

#000110465914036479 Filed on May 08, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$KPTI
Karyopharm Therapeutics Inc. Stock $kpti